Respiratory Syncytial Virus Infections
Conditions
Brief summary
To provide safety, tolerability, pharmacokinetic, and immunogenicity data for MEDI-524 administered initially as a single dose to healthy adults in a dose escalation safety study before testing in the targeted pediatric population.
Interventions
BIOLOGICALMEDI-524 (Numax-TM)
Grp.1: 3 mg/kg IV (single dose)
Sponsors
MedImmune LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 49 Years
Healthy volunteers
Yes
Inclusion criteria
* Volunteers must meet all of the following criteria: * Age 18 through 49 years at the time of administration of study drug * Weight £90 kg * Healthy by medical history and physical examination * Normal electrocardiogram (EKG) at screening (must be within 21 days before entry into the study) * Written informed consent obtained from the volunteer * Sexually active females, unless surgically sterile, must have used an effective method of avoiding pregnancy (including oral or implanted contraceptives, IUD, female condom, diaphragm with spermicide, cervical cap, abstinence, use of a condom by the sexual partner or sterile sexual partner) for 14 days prior to the administration of study drug, must agree to continue using such precautions for 30 days after administration of study drug, and must have a negative serum pregnancy test within 7 days prior to the administration of study drug and a negative urine pregnancy test on the day of study drug administration. * Ability to complete the follow-up period of 90 days (single-dose groups) or 120 days (two-dose group) as required by the protocol
Exclusion criteria
* Volunteers must have none of the following: * Acute illness at the time of entry into the study * Temperature ³99.5°F at the time of entry into the study * Any drug therapy within 7 days prior to Study Day 0 (except for certain medications such as contraceptives, topical corticosteroids, or infrequent use of over-the-counter headache medications, following approval of the sponsor) * Blood donation in excess of 400 mL within 6 months of the time of entry into the study * Receipt of immunoglobulin or blood products within 60 days before entry into the study * Receipt of any investigational drug therapy or standard vaccine within 120 days before administration of study drug in this protocol through 60 days after the final dose of study drug * History of immunodeficiency or receipt of immunosuppressive drugs * History of allergic disease or reactions likely to be exacerbated by any component of the study drug * Previous medical history or evidence of an intercurrent illness that may compromise the safety of the volunteer in the study * Evidence of any systemic disease on physical examination * Evidence of infection with hepatitis A, B, or C virus or HIV-1 * At screening (must be within 7 days before study dose administration) any of the following: CBC: Hgb \< 12.0 gm/dL; WBC \< 4,000/mm3; platelet count \< 120,000/mm3 (or laboratory normal values); AST, ALT, BUN, creatinine \> upper limit of normal; other abnormal laboratory values in the screening panel which in the opinion of the principal investigator are judged to be clinically significant. * Nursing mother * History of alcohol or drug abuse within the past 2 years * The presence of any condition or concern which in the opinion of the principal investigator may interfere with the conduct or interpretation of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety | 30 days after patient's final dose of study drug |
| Pharmacokinetics | Study Day 0 and 60, 90 days after dose 1; and 7, 30, 60, 90 days after dose 2. |
| Immunogenicity | 150 days after final dose |
Countries
United States
Outcome results
None listed